Holen Sie sich die Stockscreener-App
31.38
0.48%
0.15
Schlusskurs vom Vortag:
$31.23
Offen:
$31.23
24-Stunden-Volumen:
14.40M
Relative Volume:
0.70
Marktkapitalisierung:
$7.14B
Einnahmen:
$1.78B
Nettoeinkommen (Verlust:
$164.40M
KGV:
45.48
EPS:
0.69
Netto-Cashflow:
$236.51M
1W Leistung:
-0.98%
1M Leistung:
-14.87%
6M Leistung:
-39.48%
1J Leistung:
+12.31%
1-Tages-Spanne:
$30.64
$31.82
1-Wochen-Bereich:
$29.92
$33.27
52-Wochen-Spanne:
$23.97
$72.98
Hims Hers Health Inc Stock (HIMS) Company Profile
Firmenname
Hims Hers Health Inc
Sektor
Telefon
415-851-0195
Adresse
2269 CHESTNUT ST, SAN FRANCISCO
Vergleichen Sie HIMS mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
HIMS
Hims Hers Health Inc
|
31.38 | 7.11B | 1.78B | 164.40M | 236.51M | 0.69 |
|
ZTS
Zoetis Inc
|
124.65 | 55.21B | 9.40B | 2.65B | 2.24B | 5.935 |
|
TAK
Takeda Pharmaceutical Co Adr
|
16.16 | 51.59B | 29.63B | 260.53M | 5.51B | 0.0788 |
|
HLN
Haleon Plc Adr
|
9.83 | 43.51B | 14.26B | 1.98B | 2.47B | 0.4327 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
31.76 | 37.11B | 16.88B | 666.71M | 251.19M | 0.6132 |
|
UTHR
United Therapeutics Corp
|
464.93 | 20.32B | 3.08B | 1.24B | 1.07B | 25.61 |
Hims Hers Health Inc Stock (HIMS) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-01-12 | Eingeleitet | Evercore ISI | In-line |
| 2025-12-09 | Eingeleitet | Barclays | Overweight |
| 2025-10-21 | Eingeleitet | KeyBanc Capital Markets | Sector Weight |
| 2025-06-23 | Herabstufung | Needham | Buy → Hold |
| 2025-06-04 | Bestätigt | Needham | Buy |
| 2025-04-29 | Herabstufung | TD Cowen | Buy → Hold |
| 2025-02-18 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2025-01-10 | Herabstufung | Citigroup | Neutral → Sell |
| 2025-01-07 | Eingeleitet | BTIG Research | Buy |
| 2024-12-17 | Eingeleitet | Morgan Stanley | Overweight |
| 2024-11-14 | Herabstufung | BofA Securities | Buy → Underperform |
| 2024-08-22 | Eingeleitet | Needham | Buy |
| 2024-08-09 | Herabstufung | Imperial Capital | Outperform → In-line |
| 2024-05-22 | Herabstufung | Citigroup | Buy → Neutral |
| 2024-04-16 | Herabstufung | Jefferies | Buy → Hold |
| 2024-04-10 | Eingeleitet | Canaccord Genuity | Buy |
| 2024-02-28 | Hochstufung | Imperial Capital | In-line → Outperform |
| 2024-02-26 | Eingeleitet | Leerink Partners | Market Perform |
| 2023-12-07 | Eingeleitet | Imperial Capital | In-line |
| 2023-07-28 | Eingeleitet | TD Cowen | Outperform |
| 2023-04-11 | Eingeleitet | Robert W. Baird | Neutral |
| 2023-02-09 | Hochstufung | Jefferies | Hold → Buy |
| 2022-11-08 | Hochstufung | BofA Securities | Neutral → Buy |
| 2022-11-08 | Hochstufung | SVB Leerink | Mkt Perform → Outperform |
| 2022-10-17 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2022-09-07 | Eingeleitet | Truist | Hold |
| 2022-07-15 | Eingeleitet | SVB Leerink | Underperform |
| 2022-04-14 | Eingeleitet | Guggenheim | Buy |
| 2022-04-01 | Fortgesetzt | Credit Suisse | Outperform |
| 2022-03-10 | Eingeleitet | Deutsche Bank | Hold |
| 2021-12-02 | Eingeleitet | Jefferies | Hold |
| 2021-11-11 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2021-07-06 | Eingeleitet | BofA Securities | Neutral |
| 2021-05-20 | Hochstufung | Credit Suisse | Neutral → Outperform |
| 2021-04-21 | Eingeleitet | Truist | Hold |
| 2021-03-09 | Eingeleitet | Credit Suisse | Neutral |
| 2021-03-02 | Hochstufung | Citigroup | Neutral → Buy |
| 2021-02-17 | Eingeleitet | Citigroup | Neutral |
| 2021-02-12 | Eingeleitet | Piper Sandler | Neutral |
| 2021-02-08 | Eingeleitet | Tigress Financial | Buy |
Alle ansehen
Hims Hers Health Inc Aktie (HIMS) Neueste Nachrichten
Published on: 2026-01-18 05:20:30 - baoquankhu1.vn
Portfolio Recap: Does SKLZ stock benefit from AI growthJuly 2025 Volume & Daily Risk Controlled Trade Plans - baoquankhu1.vn
Market Review: Is Hims Hers Health Inc a top pick in the sectorMarket Risk Report & Fast Gain Swing Trade Alerts - baoquankhu1.vn
Hims GLP-1 Weight Loss Guide 2026: Injectable and Oral Treatment Options for Men (Semaglutide and Tirzepatide) - Newswire.com
Hims & Hers And HIMZ: Short‑Term Pain From Novo, Long‑Term Opportunity Still Bright (HIMS) - Seeking Alpha
Looking For A Short Squeeze? 10 Stocks Ready To Rocket - Benzinga
Is Most-Watched Stock Hims & Hers Health, Inc. (HIMS) Worth Betting on Now? - Yahoo Finance
Hims & Hers Shares Face Heightened Volatility on Key Expiry Date - AD HOC NEWS
Lawsuit alleges Lilly, Novo locked up telehealth to kill compounded GLP-1s - Sherwood News
Best Healthcare Stocks To ConsiderJanuary 5th - MarketBeat
Promising Healthcare Stocks To Follow NowJanuary 14th - MarketBeat
BofA Maintains an Underperform Rating on Hims & Hers Health, Inc. (HIMS) - Insider Monkey
Hims & Hers: Growth Catalysts Or Margin Trap (NYSE:HIMS) - Seeking Alpha
A Look At Hims & Hers Health (HIMS) Valuation As Amazon Targets The Weight Loss Segment - Sahm
Hims & Hers Health, Inc. (HIMS) Earnings Expected to Grow: What to Know Ahead of Next Week's Release - MSN
OMCL vs. HIMS: Which Stock Is the Better Value Option? - Yahoo Finance
Belvedere Trading LLC Sells 35,095 Shares of Hims & Hers Health, Inc. $HIMS - MarketBeat
Why Hims & Hers Health (HIMS) Is Down 6.8% After Amazon Pharmacy Adds Wegovy Weight-Loss Pill - Yahoo Finance
Why Hims & Hers Health, Inc. (HIMS) Outpaced the Stock Market Today - sharewise.com
Hims & Hers Health (HIMS) Receives Sell Rating Amid Overvaluatio - GuruFocus
Is It Too Late To Consider Hims & Hers Health (HIMS) After Its 4x Three-Year Surge? - Sahm
Key facts: Hims & Hers Health faces challenges; Evercore sets price target at $33 - TradingView — Track All Markets
4 Analysts Have This To Say About Hims & Hers Health - Benzinga
HIMS: Bullish Momentum Observed as Shares Rise - GuruFocus
Best Healthcare Stocks To Follow TodayJanuary 12th - MarketBeat
Hims & Hers Expands Platform-Led Access to Provider-Directed Care - The Globe and Mail
Hims & Hers stock is crashing: will it rebound soon? - TradingView — Track All Markets
Evercore ISI Initiates Coverage on Hims (HIMS) with In-Line Rati - GuruFocus
Hims & Hers Health (NYSE:HIMS) Coverage Initiated at Evercore ISI - MarketBeat
Evercore ISI initiates Hims and Hers stock coverage with In Line rating - Investing.com Canada
Hims & Hers Health (HIMS) stock slides premarket after Amazon’s Wegovy pill move — what traders watch next - TechStock²
Why is HIMS stock slipping premarket today? - MSN
Why Is HIMS Stock Slipping Premarket Today? - Stocktwits
Is It Too Late To Consider Hims & Hers Health (HIMS) After Recent Share Price Pullback - Yahoo Finance
A Look At Hims & Hers Health (HIMS) Valuation As Telehealth And Recurring Care Draw Fresh Attention - Yahoo Finance
Trading Systems Reacting to (HIMS) Volatility - Stock Traders Daily
Hims & Hers Expands Care Scope as Prescription Platforms Evolve - MSN
After a 36% Rally in 2025, Is HIMS Stock Still a Good Buy Right Now? - TIKR.com
Hims & Hers Health Inc. Stock (HIMS) Opinions on Recent Price Target Cut - Quiver Quantitative
$HIMS stock fell 6% this week. Here's what we see in our data. - Quiver Quantitative
Hims & Hers stock slides as Amazon adds Wegovy pill, raising fresh pricing fears - TechStock²
Hims & Hers health authorizes $250 million share repurchase program - MSN
Hims & Hers stock slides as Amazon starts selling Novo Nordisk’s new Wegovy pill - TechStock²
Hims & Hers Health: Capitalizing On Healthcare Innovation (NYSE:HIMS) - Seeking Alpha
Hims & Hers Stock: A Pivotal Year of Investment and Uncertainty - AD HOC NEWS
Hims & Hers Health stock falls after Amazon Pharmacy adds Wegovy pill - Investing.com Canada
Amazon Pharmacy to offer Wegovy pill for as little as $25 a month (AMZN:NASDAQ) - Seeking Alpha
Hims & Hers Health, Inc. $HIMS Shares Sold by SG Americas Securities LLC - MarketBeat
Hims & Hers CEO Bets On Personalized Healthcare And AI In 2026 — Wall Street Braces For A Costly Year - Stocktwits
Hims & Hers Growth Story Has A Lot To Prove In 2026 (NYSE:HIMS) - Seeking Alpha
Hims & Hers Plunges 39.2% in 3 Months: Time to Hold the Stock or Sell? - The Globe and Mail
Finanzdaten der Hims Hers Health Inc-Aktie (HIMS)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.30%
1.45%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):